A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML)

Acute Myelogenous Leukemia Clinical Trial

Official title:

A Phase I, Open-label, Multi-center Study of Clofarabine (JC0707) in Japanese Patients With Acute Myeloid Leukemia (AML)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01090167
• Other study ID #: CLOAML10508
• Status: Completed
• Phase: Phase 1
• First received: March 18, 2010
• Last updated: March 17, 2014
• Start date: February 2010
• Est. completion date: April 2011

Study information

• Verified date: March 2014
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Pharmaceuticals and Medical Devices AgencyJapan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

This study is sponsored by Genzyme Japan K.K. The purpose of this study is to assess the safety, tolerability and pharmacokinetics of Clofarabine (JC0707) intravenously administered to Japanese adult patients with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) at 20, 30, and 40 mg/m2/day on a 5-day dose schedule.

Description:

This is a Phase I, open-label, multi-center study of Clofarabine administered to Japanese patients with Acute Myeloid Leukemia (AML) who are relapsed/refractory or elderly untreated AML for whom standard induction chemotherapy is unlikely to be of benefit.

Cohort 1 will receive 20 mg/m2/day of Clofarabine once daily for five consecutive days, Cohort 2 will receive 30 mg/m2/day, and Cohort 3 will receive 40 mg/m2/day. Patients will receive one cycle as a rule. However, if there is evidence of some hematologic response after one cycle of treatment with Clofarabine, patients may receive up to a maximum of three cycles. If patients fail to achieve CR or CRp after two cycles of treatment with Clofarabine, further dosing for such patients should be stopped.

Three patients constituting a cohort will receive Clofarabine and will then be assessed for dose limiting toxicities (DLT) at Cycle 1. If none of these three patients develops DLT, the next cohort will be introduced. If one of them develops DLT, three new patients will be added to the cohort, so that six patients in total are included in the tolerability assessment. In this case, treatment of the next cohort is allowed only in the case the number of patients who develop DLT is still one in this six-patient cohort. If two of the six patients develop DLT, however, the tolerability is ruled out. However, if two DLTs are observed at the 20mg/m2/day dose cohort, new patients will be enrolled at cohort -1 15mg/m2/day; and if no more than one of six patients in the cohort develop DLT, it will be considered as the last cohort for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 74 Years

Eligibility

Inclusion Criteria:

• Patients having diagnosis of relapsed or refractory Acute Myeloid Leukemia (AML) according to the World Health Organization (WHO) criteria or untreated AML patients (60 years to 74 years) for whom standard induction chemotherapy is unlikely to be of benefit as judged by the investigator (or co-investigator)

• Age at the time of informed consent 20 years up to 74 years; 60 years or older for patients with previously untreated AML

• Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

• Be able to comply with the study procedures and follow-up examinations specified in this protocol.

• Hepatic, renal, pancreatic, and cardiac function satisfying the laboratory values criteria

Exclusion Criteria:

• Patients having diagnosis of acute promyelocytic leukemia(APL, French-American-British classification M3 or WHO classification of APL with t(15;17)(q22;q12), (PML/RARA and variants)

• Have had prior hematologic stem cell transplant

• Have had prior external beam radiation therapy to the pelvis

• Have systemic fungal, bacterial, viral, or other infection that cannot be controlled and is exhibiting symptoms related to the infection despite appropriate treatment. In addition, patients must have a temperature less than 38.0 for at least 48 hours prior to the first dose of the study drug.

• Have any other severe concurrent disease that is difficult to control by drug therapies, or have a history of serious organ dysfunction or disease involving the liver, kidney, pancreas, heart, or other organ system that may place the patient at undue risk

• Diagnosis of another malignancy, unless the patient meets none of the following conditions: 1) Any persisting treatment-related adverse events; 2) Less than 180 days of disease-free duration counted during the period from the treatment completion to enrollment; note that the patients meeting any of the following conditions is eligible:

• Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia are eligible for this study if treatment for the condition has been completed.

• Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.

• Have a prior positive test for HBs antigen or antibody, HBc antibody, HCV antibody, or HIV antigen or antibody; note that the patients who have had treatment of vaccine and positive for HBs antibody is eligible.

• Have a clinically significant arrhythmia at screening or a known family history of QT prolongation. Marked prolongation of QTc interval exceeding 450 msec is considered clinically significant

• Have clinical evidence suggestive of central nervous system (CNS) involvement with leukemia

• Have a Psychiatric disorders that would interfere with consent, study participation, or follow-up

• Have had prior treatment with the study drug

• Have had any other chemotherapy or investigational agent received within 30 days prior to the first dose of the study drug

• If received any chemotherapy or investigational agent prior to this time point, drug-related adverse events must be recovered to the baseline value or Grade 1 or less prior to the first dose of the study drug (except for alopecia, and nail changes).

• Is currently participating in another concurrent investigational protocol

• Are pregnant or lactating.

• Male and female patients who are fertile must agree to use an effective means of birth control to avoid pregnancy during the study period and for six months after the last dose of study drug.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Myelogenous Leukemia
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Intervention

Drug:
• clofarabine
Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2

Locations

Country	Name	City	State
Japan	Nagoya Daini Red Cross Hospital	Aichi
Japan	National Hospital Organization Nagoya Medical Center	Aichi
Japan	University of Fukui Hospital	Fukui
Japan	Tokai University Hospital	Kanagawa
Japan	Jichi Medical University Hospital	Tochigi
Japan	Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Genzyme, a Sanofi Company

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum Tolerated Dose (MTD) as determined by Dose Limiting Toxicities (DLTs)		28 days (1st cycle)	Yes
Primary	Safety as measured by number of patients with at least one adverse events (incidence)		50 days	Yes
Primary	Safety as measured by severity of adverse events		50 days	Yes
Primary	Safety as measured by duration of adverse events		50 days	Yes
Primary	Safety as measured by causality of adverse events		50 days	Yes
Primary	Safety as measured by seriousness of adverse events		50 days	Yes
Primary	Safety as measured by type of adverse event		50 days	Yes
Primary	Safety as measured by number of deaths		50 days	Yes
Primary	Safety as measured by number of serious adverse events		50 days	Yes
Primary	Safety as measured by number of patients who discontinue due to adverse events		50 days	Yes
Primary	Safety as measured by clinically significant changes in hematology		50 days	Yes
Primary	Safety as measured by clinically significant changes in chemistry parameters (i.e. serum chemistry)		50 days	Yes
Primary	Pharmacokinetic (PK) parameters (Cmax, Tmax, AUC)		6 days	No